Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Adenocarcinoma × Radium-223 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18 Neoplasm Metastasis 2 Prostatic Neoplasms, Castration-Resistant 1 Prostate Adenocarcinoma 1 Pain 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Fatigue 1 Castration-resistant Prostate Cancer 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Biochemical Recurrent Prostate Cancer 1

Interventions

Magnetic Resonance Spectroscopy 5 Radiosurgery 4 luprolide acetate gel depot 3 enzalutamide 3 Radiotherapy 3 Radiation 3 Leuprolide 3 Goserelin 3 relugolix 2 gallium 68 PSMA-11 2 bicalutamide 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 Triptorelin Pamoate 2 Specimen Handling 2 Proton Therapy 2 Biopsy 2 radium Ra 223 dichloride 1 niraparib 1 histrelin 1 fluciclovine F-18 1 flibanserin 1 entinostat 1 darolutamide 1 atezolizumab 1 apalutamide 1 abiraterone 1 X-Rays 1 Watchful Waiting 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04704505 2026-02-06

BAT-RAD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡